MedWatch

Analyst identifies some positive elements in Demant report despite downgrade

Although the Danish hearing aid manufacturer just revised its financial expectations for the full year, it hasn’t all been bad for Demant in the second quarter, a Sydbank analyst concludes.

Photo: Dado Ruvic/Reuters/Ritzau Scanpix

Hearing aid manufacturer Demant has been fighting an uphill battle in the first half of the year, but there are still a few positive takeaways from the Danish company’s financial report, which was made public on Tuesday.

In the report, Demant downgraded its expectations for 2022 based on weaker performances within retail hearing aid sales and its headset and gaming equipment businesses.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs